Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Northrop Grumman Corporation

NOC
Industrials · Aerospace & Defense

Northrop Grumman Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is building a base (22 weeks in) while the P/E sits at the 44th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −6.8% year on year, and 125% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$531
−7.4% 1Y
P/E
16.9×
44th pctile
of its own 5-year range
Revenue (Jun 26)
$10.9 B
+5.1% YoY
Profit (Jun 26)
$1.1 B
−6.8% YoY
Operating margin
10.1%
−3.7 pp YoY
ROE
27%
FY25
ROIC
15.0%
vs WACC 3.6% → +11.4 pp
Cash conversion
125%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Northrop Grumman Corporation trades at $531, building a base and 22 weeks into that stage. That is −11.7% against its own 200-day average. It sits at 12% of a 52-week range of $500 to $756. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.

Today the stock is building a base — week 22 of stage 1. At $531 it trades −11.7% versus its 200-day average and sits at 12% of its 52-week range ($500–$756).

Sep 26: $531 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−11.7% versus the 200-day line, week 22 of stage 1
Price50-day avg200-day avg
S3S2S2S1$783$686$590$493$397$$531$601Sep 23Jun 24Mar 25Dec 25Sep 26
S3S2S2S1$783$686$590$493$397$$531$601Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (533 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +139% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Northrop Grumman Corporation trades at 16.9× P/E, mid-range by its own standards (44th percentile). Its long-run median P/E is 17.4×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 16.9× is mid-range by its own standards (44th percentile), against a long-run median of 17.4× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 16.9× vs a 17.4× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.5-year window; loss-period spikes above 35× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (44th percentile)
P/EMedianEPS (TTM) (quarterly)
36.6×$39.230.0×$29.423.5×$19.616.9×$9.810.3×$0.0×$16.86×$32Apr 22May 23Jun 24Aug 25Sep 26
36.6×$39.230.0×$29.423.5×$19.616.9×$9.810.3×$0.0×$16.86×$32Apr 22Jun 24Sep 26
PEG 3.04 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.4×4.9×3.3×1.7×0.2××3.04×Sep 21Sep 22Dec 23Mar 25Jun 26
6.4×4.9×3.3×1.7×0.2××3.04×Sep 21Dec 23Jun 26
P/E
16.9×
44th percentile of 5y
PEG
3.23
as reported

Why the multiple sits where it does: over the past year annual EPS moved +2.6% against a −7.4% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +7.0%/yr price move, ~+1.4%/yr came from earnings growth and ~+5.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Northrop Grumman Corporation reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +72.8% at its peak to +14.2% but is still expanding, ROCE holding at 12.5%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +2.2% in FY25, profit +0.2% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
7.7%123%6.2%74%4.8%26%3.3%−23%1.8%−71%%%2.2%0.2%FY21FY23FY25
7.7%123%6.2%74%4.8%26%3.3%−23%1.8%−71%%%2.2%0.2%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit rolling over
RevenueProfitEPS
11%124%7.7%75%4.7%26%1.6%−23%−1.4%−72%%%5.9%14.2%16%Sep 23Dec 24Jun 26
11%124%7.7%75%4.7%26%1.6%−23%−1.4%−72%%%5.9%14.2%16%Sep 23Dec 24Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
14%12%11%8.9%7.1%%12.5%Sep 23Mar 24Dec 24Sep 25Jun 26
14%12%11%8.9%7.1%%12.5%Sep 23Dec 24Jun 26
Revenue growth
Recovering
latest +5.9% · span −0.6% to +9.9%
Profit growth
Rolling over
latest +14.2% · span −58.2% to +103.4%
EPS growth
Rolling over
latest +16.0% · span −57.2% to +110.2%
ROCE
Stuck low
latest 12.5% · span 7.6%–13.8%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+2.2%+4.7%
Profit+0.2%−5.2%
EPS+2.6%−2.6%
Stock price−7.4%+7.0%+8.7%+9.7%
Revenue YoY (Jun 26)
+5.1%
latest quarter vs a year ago
Profit YoY (Jun 26)
−6.8%
latest quarter vs a year ago
Revenue 10y
4.1%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.9/100 — rank 15 of 30 in Aerospace & Defense · 81% evidence confidence

Northrop Grumman Corporation scores 44.9 out of 100 against the 30 companies it is compared with in Aerospace & Defense, ranking 15. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.

The four contributions add to the total exactly: 9.9 + 10.7 + 14.5 + 9.8 = 44.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Northrop Grumman Corporation reported $10.9 B of revenue in the Jun 26 quarter, +5.1% year on year. That is the 5th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.1% a year. The last full year, FY25, came in at $42.0 B. The last four reported quarters add to $42.9 B.

FY25 revenue came in at $42.0 B (+2.2% on the year), capping 4 years at 4.1% compound. The latest quarter (Jun 26) printed $10.9 B, +5.1% year on year — the 5th consecutive quarter of year-over-year growth.

FY25 revenue $42.0 B (+2.2% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.1% a year over 4 years
RevenueYoY growth
457.7%346.2%234.8%113.3%0.01.8%$ B%$42B2.2%FY21FY23FY25
457.7%346.2%234.8%113.3%0.01.8%$ B%$42B2.2%FY21FY23FY25
Jun 26: $10.9 B (+5.1% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
5th straight quarter of growth
Revenue (quarterly)YoY growth
1311%9.56.1%6.31.5%3.2−3.1%0.0−7.8%$ B%$11B5.1%Sep 23Dec 24Jun 26
1311%9.56.1%6.31.5%3.2−3.1%0.0−7.8%$ B%$11B5.1%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +5.8% growth against the decade's 4.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +5.9% over the last 4 quarters against +2.6%/yr over the last 8 — accelerating; TTM profit +14.2% vs +40.5%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Northrop Grumman Corporation's operating margin is 10.1% in the Jun 26 quarter, −3.7 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.5% to 15.8%. The current quarter sits inside that band.

The latest quarter's operating margin is 10.1%, −3.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.5%–15.8%.

🚨 Why the margin moved: operating margin went −3.7 pp year on year while gross margin went −1.9 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 10.8% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 6.5–15.8% band over 5 years
operating marginYoY change (pp)
17%5.0%14%2.1%11%−0.9%8.5%−3.9%5.8%−6.8%%%10.8%0.1%FY21FY23FY25
17%5.0%14%2.1%11%−0.9%8.5%−3.9%5.8%−6.8%%%10.8%0.1%FY21FY23FY25
Jun 26: 10.1% operating margin (−3.7 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%16%10%8.3%5.1%0.6%0.0%−7.2%−5.1%−15%%%10.1%−3.7%Sep 23Dec 24Jun 26
15%16%10%8.3%5.1%0.6%0.0%−7.2%−5.1%−15%%%10.1%−3.7%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Northrop Grumman Corporation earned $1.1 B of net profit in the Jun 26 quarter, −6.8% year on year. Full-year FY25 profit was $4.2 B. The 4-year compound rate is −12.1%. That is 10.0% of the quarter's revenue. The same quarter a year earlier earned $1.2 B. 1 of the last 12 reported quarters were loss-making.

Jun 26 profit was $1.1 B, −6.8% year on year. On the full year, FY25 printed $4.2 B (+0.2%), and the 4-year compound rate is −12.1%.

FY25 profit $4.2 B (+0.2% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
−12.1% a year over 4 years
Net profitYoY growth
7.6115%5.769%3.822%1.9−24%0.0−71%$ B%$4B0.2%FY21FY23FY25
7.6115%5.769%3.822%1.9−24%0.0−71%$ B%$4B0.2%FY21FY23FY25
Jun 26: $1.1 B (−6.8% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
1.6100%1.039%0.4−21%−0.1−82%−0.7−143%$ B%$1B−6.8%Sep 23Dec 24Jun 26
1.6100%1.039%0.4−21%−0.1−82%−0.7−143%$ B%$1B−6.8%Sep 23Dec 24Jun 26

🚨 Why profit moved: revenue contributed +5.1% and the margin −3.7 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +24.2% vs revenue +5.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 125% of Northrop Grumman Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $4.8 B of operating cash against $4.2 B of profit. After $1.4 B of capital spending, $3.3 B was left as free cash.

FY25: operating cash of $4.8 B against reported profit of $4.2 B, leaving free cash of $3.3 B after $1.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 125% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $4.8 B vs profit $4.2 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
125% of 3-year profit arrived as cash
Operating cashNet profitFree cash
7.65.73.81.90.0$ B$5B$4B$3BFY21FY23FY25
7.65.73.81.90.0$ B$5B$4B$3BFY21FY23FY25
Jun 26: operating cash $1.3 B = 117% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
4.3321%2.7147%1.1−26%−0.5−199%−2.1−373%$ B%$1B117%Sep 23Dec 24Jun 26
4.3321%2.7147%1.1−26%−0.5−199%−2.1−373%$ B%$1B117%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Northrop Grumman Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $5.0 B over the last 3 years. Averaged over those years that is 4.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $5.0 B over the last 3 fiscal years.

FY25: capex $1.4 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.91.41.00.50.0$ B$1BFY21FY23FY25
1.91.41.00.50.0$ B$1BFY21FY23FY25
Jun 26: capex $0.3 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.93.60.72.20.40.70.2−0.80.0−2.2$ B$ B$0B$1BSep 23Dec 24Jun 26
0.93.60.72.20.40.70.2−0.80.0−2.2$ B$ B$0B$1BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Northrop Grumman Corporation earns a ROE of 25% in FY25. That is up from a trough of 14% in FY23. Return on invested capital clears the cost of that capital by +11.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.0% net margin on 0.82× asset turns.

FY25 ROE is 25%, recovered from a FY23 trough of 14% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 10.0% net margin × 0.82× asset turns × 3.08× balance-sheet leverage ≈ 25.3% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 15.0% − 3.6% = a +11.4 pp spread. The 3.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

FY25: ROE 25% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 3.6% cost of capital used on this page.
the climb back from FY23's 14%
ROEROIC (annual)WACC
58%43%29%14%0.0%%25.1%13.1%FY21FY23FY25
58%43%29%14%0.0%%25.1%13.1%FY21FY23FY25
Jun 26: ROIC 12.9% (TTM) vs WACC 3.6% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
35%26%18%9.7%1.3%%12.9%28.2%Sep 23Dec 24Jun 26
35%26%18%9.7%1.3%%12.9%28.2%Sep 23Dec 24Jun 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Northrop Grumman Corporation paid $9.40 per share over the last four reported quarters. The most recent declaration was $2.47 for Jun 26. Against the current price of $531 that is a trailing yield of 1.77%, measured on dividends already paid rather than on a forecast.

Northrop Grumman Corporation paid $9.40 per share across the last four reported quarters, most recently $2.47 for Jun 26. Against the current price of $531 the trailing twelve months work out to 1.77% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $2.47 (Jun 26)
Dividend per share
2.72.01.30.70.0$ B$3BSep 23Mar 24Dec 24Sep 25Jun 26
2.72.01.30.70.0$ B$3BSep 23Dec 24Jun 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Northrop Grumman Corporation carries total debt of $16.3 B against shareholder equity of $17.9 B as of Jun 26, a debt-to-equity of 0.91. On the annual view that ratio went from 1.11 in FY21 to 1.02 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $16.3 B against shareholder equity of $17.9 B — a debt-to-equity of 0.91. On the annual view, debt-to-equity went from 1.11 (FY21) to 1.02 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $17.0 B at 1.02× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
181.13×141.06×9.21.00×4.60.94×0.00.87×$ B×$17B1.02×FY21FY23FY25
181.13×141.06×9.21.00×4.60.94×0.00.87×$ B×$17B1.02×FY21FY23FY25
Jun 26: debt $16.3 B, debt-to-equity 0.91 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
181.19×141.12×9.21.04×4.60.96×0.00.89×$ B×$16B0.91×Sep 23Dec 24Jun 26
181.19×141.12×9.21.04×4.60.96×0.00.89×$ B×$16B0.91×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

1.7% of Northrop Grumman Corporation's tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 3.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 1.7% of the float is sold short, and at typical trading volumes it would take about 3.6 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
1.7%
of the tradable float
Days to cover
3.6
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Northrop Grumman Corporation: the Z-score reads 3.33. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 3.33 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 3.33.

15 · Related companies · Aerospace & Defense
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Lockheed Martin CorporationLMT 72.1/100Favorable setup81% evidence TURNING 25.6/35 Revenue 7.2% · PAT 49.5% · OPM change 8.3 pp 83% evidence 14.5/25 ROCE 6.8% · OPM 12.4% 76% evidence 16.1/20 P/E 18.7× · PEG 0.35 65% evidence 15.9/20 RS sector 5.2% · RS bench -8% · 1Y 13.6%4 of 12 weeks ahead 100% evidence
Exact sum: 25.6 + 14.5 + 16.1 + 15.9 = 72.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2RTX CorporationRTX 65.8/100Favorable setup81% evidence BREAKING OUT 21.5/35 Revenue 11.8% · PAT 26.1% · OPM change 1.2 pp 83% evidence 15.2/25 ROCE 10.4% · OPM 12.7% 76% evidence 12.1/20 P/E 33× · PEG 1.33 65% evidence 17.0/20 RS sector 10.7% · RS bench -2.8% · 1Y 24.4%8 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 15.2 + 12.1 + 17 = 65.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3HEICO CorporationHEI 60.0/100Mixed-positive evidence81% evidence ASLEEP 24.3/35 Revenue 18.8% · PAT 30.2% · OPM change 2.9 pp 83% evidence 14.7/25 ROCE 4.3% · OPM 25.5% 76% evidence 10.4/20 P/E 48.2× · PEG 1.56 65% evidence 10.6/20 RS sector -0.7% · RS bench -12.7% · 1Y -6.1%8 of 12 weeks ahead 100% evidence
Exact sum: 24.3 + 14.7 + 10.4 + 10.6 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Elbit Systems Ltd.ESLT 59.8/100Mixed-positive evidence81% evidence ASLEEP 22.4/35 Revenue 13.7% · PAT 60.2% · OPM change 1.6 pp 83% evidence 11.7/25 ROCE 3.1% · OPM 9.6% 76% evidence 11.7/20 P/E 57.2× · PEG 1.13 65% evidence 14.0/20 RS sector 12.2% · RS bench -1.9% · 1Y 51.3%1 of 12 weeks ahead 100% evidence
Exact sum: 22.4 + 11.7 + 11.7 + 14 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Howmet Aerospace Inc.HWM 59.7/100Mixed-positive evidence81% evidence ASLEEP 24.6/35 Revenue 18.1% · PAT 33.9% · OPM change 2.5 pp 83% evidence 16.3/25 ROCE 7% · OPM 27.9% 76% evidence 9.0/20 P/E 57.9× · PEG 1.62 65% evidence 9.8/20 RS sector 2.6% · RS bench -9.8% · 1Y 19.7%3 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 16.3 + 9 + 9.8 = 59.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Embraer S.A.EMBJ 58.3/100Mixed-positive evidence66% evidence BREAKING OUT 16.5/35 Revenue 20% · PAT -22.2% · OPM change 1 pp 53% evidence 7.6/25 ROCE 1.1% · OPM 5.6% 57% evidence 14.2/20 P/E 54.9× · PEG 0.51 65% evidence 20.0/20 RS sector 21% · RS bench 6.4% · 1Y 27.7%8 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 7.6 + 14.2 + 20 = 58.3 · Decision use: Price leads the evidence: RS versus the benchmark is 6.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
7General Dynamics CorporationGD 56.7/100Thin evidence · provisional58% evidence FADING 17.0/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 12.5/25 ROCE 3.7% · OPM 10.4% 76% evidence 11.0/20 P/E 22.8× · PEG — 15% evidence 16.2/20 RS sector 8.7% · RS bench -4.4% · 1Y 11.1%6 of 12 weeks ahead 100% evidence
Exact sum: 17 + 12.5 + 11 + 16.2 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Hexcel CorporationHXL 56.0/100Thin evidence · provisional56% evidence FADING 20.8/35 Revenue — · PAT — · OPM change 1.8 pp 39% evidence 10.8/25 ROCE 2.9% · OPM 11.5% 76% evidence 10.0/20 P/E 50.3× · PEG — 15% evidence 14.4/20 RS sector 14.1% · RS bench 0.4% · 1Y 47.2%7 of 12 weeks ahead 100% evidence
Exact sum: 20.8 + 10.8 + 10 + 14.4 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9GE AerospaceGE 54.5/100Mixed-positive evidence81% evidence ASLEEP 19.4/35 Revenue 21.7% · PAT 16.2% · OPM change -0.3 pp 83% evidence 16.4/25 ROCE 11.7% · OPM 20.6% 76% evidence 7.3/20 P/E 43.5× · PEG 2.38 65% evidence 11.4/20 RS sector 4.8% · RS bench -7.8% · 1Y 3.9%8 of 12 weeks ahead 100% evidence
Exact sum: 19.4 + 16.4 + 7.3 + 11.4 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Curtiss-Wright CorporationCW 52.7/100Mixed-positive evidence81% evidence ASLEEP 21.8/35 Revenue 10.5% · PAT 20% · OPM change 1.5 pp 83% evidence 19.5/25 ROCE 17.4% · OPM 19.4% 76% evidence 7.4/20 P/E 51.7× · PEG 2.28 65% evidence 4.0/20 RS sector -6.4% · RS bench -17.9% · 1Y 10.7%0 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 19.5 + 7.4 + 4 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Woodward, Inc.WWD 52.6/100Thin evidence · provisional56% evidence ASLEEP 20.4/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence 14.3/25 ROCE 4.9% · OPM 14.7% 76% evidence 9.9/20 P/E 50.5× · PEG — 15% evidence 8.0/20 RS sector -0.2% · RS bench -12.5% · 1Y 33.7%1 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 14.3 + 9.9 + 8 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Loar Holdings Inc.LOAR 50.3/100Thin evidence · provisional56% evidence ASLEEP 18.7/35 Revenue 26.3% · PAT 91.7% · OPM change -1.3 pp 53% evidence 10.3/25 ROCE 1.8% · OPM 21.5% 57% evidence 9.1/20 P/E 80.7× · PEG — 15% evidence 12.2/20 RS sector -0.4% · RS bench -12.4% · 1Y -19.2%7 of 12 weeks ahead 100% evidence
Exact sum: 18.7 + 10.3 + 9.1 + 12.2 = 50.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Leonardo DRS, Inc.DRS 49.0/100Thin evidence · provisional56% evidence ASLEEP 20.3/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence 11.8/25 ROCE 3.3% · OPM 9.1% 76% evidence 10.7/20 P/E 35.9× · PEG — 15% evidence 6.2/20 RS sector -4% · RS bench -15.9% · 1Y -10.5%2 of 12 weeks ahead 100% evidence
Exact sum: 20.3 + 11.8 + 10.7 + 6.2 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Textron Inc.TXT 46.2/100Thin evidence · provisional56% evidence BASING 15.9/35 Revenue — · PAT — · OPM change -0.8 pp 39% evidence 9.3/25 ROCE 2% · OPM 6.3% 76% evidence 11.3/20 P/E 17.4× · PEG — 15% evidence 9.7/20 RS sector -2.9% · RS bench -14.9% · 1Y -3.5%1 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 9.3 + 11.3 + 9.7 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Northrop Grumman Corporationthis pageNOC 44.9/100Mixed-negative evidence81% evidence TURNING 9.9/35 Revenue 5.9% · PAT 14% · OPM change -3.7 pp 83% evidence 10.7/25 ROCE 3% · OPM 10.1% 76% evidence 14.5/20 P/E 16.2× · PEG 1.01 65% evidence 9.8/20 RS sector -5.5% · RS bench -17.5% · 1Y -7.4%0 of 12 weeks ahead 100% evidence
Exact sum: 9.9 + 10.7 + 14.5 + 9.8 = 44.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
16Axon Enterprise, Inc.AXON 44.8/100Mixed-negative evidence71% evidence BREAKING OUT 20.0/35 Revenue 34.6% · PAT -39% · OPM change 5.4 pp 83% evidence 6.4/25 ROCE 0.9% · OPM 5.2% 76% evidence 8.6/20 P/E 232.6× · PEG — 15% evidence 9.8/20 RS sector -6.2% · RS bench -17.4% · 1Y -39.5%11 of 12 weeks ahead 100% evidence
Exact sum: 20 + 6.4 + 8.6 + 9.8 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17CAE Inc.CAE 44.4/100Mixed-negative evidence66% evidence ASLEEP 10.7/35 Revenue 4.4% · PAT -22.4% · OPM change -7.6 pp 53% evidence 10.7/25 ROCE 2% · OPM 12.9% 57% evidence 14.7/20 P/E 37.3× · PEG 0.68 65% evidence 8.3/20 RS sector -6.5% · RS bench -18.1% · 1Y -14%0 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 10.7 + 14.7 + 8.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
18The Boeing CompanyBA 43.8/100Mixed-negative evidence64% evidence ASLEEP 19.8/35 Revenue 24.8% · PAT — · OPM change 1.4 pp 62% evidence 4.1/25 ROCE 0.3% · OPM 0.6% 76% evidence 9.0/20 P/E 93.7× · PEG — 15% evidence 10.9/20 RS sector -1.2% · RS bench -13.4% · 1Y -6.3%0 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 4.1 + 9 + 10.9 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Huntington Ingalls Industries, Inc.HII 43.6/100Thin evidence · provisional56% evidence BASING 16.6/35 Revenue — · PAT — · OPM change -0.9 pp 39% evidence 9.4/25 ROCE 2.2% · OPM 5% 76% evidence 11.4/20 P/E 16.7× · PEG — 15% evidence 6.2/20 RS sector -11.8% · RS bench -23.2% · 1Y 1.1%0 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 9.4 + 11.4 + 6.2 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20StandardAero, Inc.SARO 42.9/100Thin evidence · provisional56% evidence ASLEEP 18.4/35 Revenue 15% · PAT 100% · OPM change -0.2 pp 53% evidence 9.2/25 ROCE 2.8% · OPM 8.8% 57% evidence 10.9/20 P/E 29.4× · PEG — 15% evidence 4.4/20 RS sector -10.4% · RS bench -21.6% · 1Y -16.1%4 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 9.2 + 10.9 + 4.4 = 42.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21TransDigm Group IncorporatedTDG 41.7/100Mixed-negative evidence81% evidence ASLEEP 15.3/35 Revenue 16.6% · PAT 10.3% · OPM change -1.6 pp 83% evidence 15.9/25 ROCE 5.5% · OPM 44.8% 76% evidence 5.3/20 P/E 40.2× · PEG 4.28 65% evidence 5.2/20 RS sector -9.4% · RS bench -20.5% · 1Y -15.8%0 of 12 weeks ahead 100% evidence
Exact sum: 15.3 + 15.9 + 5.3 + 5.2 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Rocket Lab CorporationRKLB 40.5/100Mixed-negative evidence61% evidence ASLEEP 25.1/35 Revenue 52.6% · PAT — · OPM change 16.7 pp 62% evidence 3.1/25 ROCE -2.4% · OPM -24.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.3/20 RS sector -9.3% · RS bench -20.5% · 1Y 33.3%2 of 12 weeks ahead 100% evidence
Exact sum: 25.1 + 3.1 + 10 + 2.3 = 40.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.3% and the one-year return is 33.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
23L3Harris Technologies, Inc.LHX 39.8/100Thin evidence · provisional58% evidence BASING 17.3/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence 10.2/25 ROCE 1.9% · OPM 11.1% 76% evidence 8.8/20 P/E 96× · PEG — 15% evidence 3.5/20 RS sector -13% · RS bench -24% · 1Y -11.7%0 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 10.2 + 8.8 + 3.5 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24FTAI Aviation Ltd.FTAI 38.4/100Thin evidence · provisional56% evidence ASLEEP 12.8/35 Revenue — · PAT — · OPM change -9.6 pp 39% evidence 13.4/25 ROCE 5% · OPM 20.5% 76% evidence 9.2/20 P/E 58.8× · PEG — 15% evidence 3.0/20 RS sector -8% · RS bench -19.9% · 1Y 6.1%0 of 12 weeks ahead 100% evidence
Exact sum: 12.8 + 13.4 + 9.2 + 3 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25AeroVironment, Inc.AVAV 37.7/100Mixed-negative evidence71% evidence BASING 17.6/35 Revenue 100% · PAT -702.3% · OPM change 3.9 pp 83% evidence 6.1/25 ROCE 1.8% · OPM 8.9% 76% evidence 8.7/20 P/E 97.8× · PEG — 15% evidence 5.3/20 RS sector -28.4% · RS bench -37.4% · 1Y -43.8%2 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 6.1 + 8.7 + 5.3 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Kratos Defense & Security Solutions, Inc.KTOS 37.1/100Thin evidence · provisional56% evidence ASLEEP 18.2/35 Revenue 21.9% · PAT 50% · OPM change -0.9 pp 53% evidence 6.4/25 ROCE 0.2% · OPM 1.3% 57% evidence 8.5/20 P/E 423.2× · PEG — 15% evidence 4.0/20 RS sector -30.2% · RS bench -39.4% · 1Y -41.1%1 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 6.4 + 8.5 + 4 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27BWX Technologies, Inc.BWXT 34.2/100Adverse evidence66% evidence ASLEEP 16.4/35 Revenue 21.4% · PAT 19% · OPM change -1.8 pp 53% evidence 11.2/25 ROCE 2.7% · OPM 9.9% 57% evidence 5.3/20 P/E 54.7× · PEG 2.86 65% evidence 1.3/20 RS sector -18.7% · RS bench -28.8% · 1Y -16.5%0 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 11.2 + 5.3 + 1.3 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Moog Inc.MOG-B 53.2/100Thin evidence · provisional33% evidence FADING 19.5/35 Revenue — · PAT — · OPM change 1 pp 32% evidence 13.1/25 ROCE 4.4% · OPM 10.8% 76% evidence 10.6/20 P/E 36.1× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y 86.1%9 of 11 weeks ahead 0% evidence
Exact sum: 19.5 + 13.1 + 10.6 + 10 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Honeywell Aerospace Inc.HONA 42.7/100Thin evidence · provisional48% evidence ASLEEP 7.2/35 Revenue 10.1% · PAT -32.7% · OPM change -10.5 pp 83% evidence 15.5/25 ROCE 8.9% · OPM 12.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence
Exact sum: 7.2 + 15.5 + 10 + 10 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Space Exploration Technologies Corp.SPCX 39.8/100Thin evidence · provisional33% evidence ASLEEP 16.4/35 Revenue — · PAT — · OPM change 17.2 pp 39% evidence 3.4/25 ROCE -1.6% · OPM -1.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence
Exact sum: 16.4 + 3.4 + 10 + 10 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Northrop Grumman Corporation's stock price today?

Northrop Grumman Corporation trades at $531, −7.4% over the past year. The company is valued at $75.0 B. The stock sits at 12% of its 52-week range of $500–$756, −11.7% versus its 200-day average. On the tape, the price is building a base, 22 weeks in. — as of 17 September 2026.

What were Northrop Grumman Corporation's latest quarterly results?

Northrop Grumman Corporation reported revenue of $10.9 B and net profit of $1.1 B for the Jun 26 quarter. Revenue rose 5.1% and profit fell 6.8% year on year. Earnings per share were $7.68. The operating margin was 10.1%, 3.7 pp lower than a year earlier. — as of 17 September 2026.

What is Northrop Grumman Corporation's revenue?

Northrop Grumman Corporation reported revenue of $10.9 B in the Jun 26 quarter, +5.1% year on year. For the full FY25 fiscal year, revenue was $42.0 B (+2.2%). Over the last 4 years revenue compounded at 4.1% a year. — as of 17 September 2026.

What is Northrop Grumman Corporation's profit?

Northrop Grumman Corporation earned $1.1 B of net profit in the Jun 26 quarter, −6.8% year on year. Full-year FY25 profit was $4.2 B. The operating margin ran 10.1% in the latest quarter. — as of 17 September 2026.

What is Northrop Grumman Corporation's market cap?

Northrop Grumman Corporation's market capitalisation is $75.0 B at a stock price of $531. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

What is Northrop Grumman Corporation's P/E ratio?

Northrop Grumman Corporation trades at a P/E of 16.9×, at the 44th percentile of its own 5-year range, against a long-run median of 17.4×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.

Does Northrop Grumman Corporation pay a dividend?

Yes — Northrop Grumman Corporation declared $2.47 per share for Jun 26, and $9.40 per share across the last four reported quarters. — as of 17 September 2026.

What is Northrop Grumman Corporation's dividend per share?

Northrop Grumman Corporation's most recently declared dividend is $2.47 per share for Jun 26, giving $9.40 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.

What is Northrop Grumman Corporation's dividend yield?

Northrop Grumman Corporation's trailing dividend yield is 1.77%: $9.40 declared per share across the last four reported quarters, against a share price of $531. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.

Is Northrop Grumman Corporation overvalued?

On its own history, Northrop Grumman Corporation looks mid-range: its P/E of 16.9× sits at the 44th percentile of its 5-year range (long-run median 17.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.

Is Northrop Grumman Corporation growing?

Not right now — Northrop Grumman Corporation's latest numbers are shrinking: latest-quarter revenue +5.1% year on year, profit −6.8%, and the margin −3.7 pp at 10.1%. The 4-year compound rates are 4.1% (revenue) and −12.1% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.

How is Northrop Grumman Corporation performing?

Northrop Grumman Corporation is building a base, 22 weeks in. Its latest quarter's revenue rose 5.1% and profit fell 6.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.

What stage is Northrop Grumman Corporation in?

Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +72.8% at its peak to +14.2% but is still expanding, ROCE holding at 12.5%. The read comes from the last 12 quarters of growth (revenue growth +5.9% latest, profit growth +14.2% latest, eps growth +16.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.

Is Northrop Grumman Corporation in an uptrend?

No — the price is building a base (week 22 of stage 1), trading −11.7% versus its 200-day average and at 12% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Northrop Grumman Corporation beating the market?

On recent form, yes — Northrop Grumman Corporation has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +139% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.

Will Northrop Grumman Corporation's stock price go up?

This page publishes no price forecast for Northrop Grumman Corporation. What it measures instead: the stock price is $531, the price is building a base 22 weeks in. Its P/E of 16.9× sits at the 44th percentile of its own 5-year range. — as of 17 September 2026.

Is the market betting against Northrop Grumman Corporation?

No — short interest is 1.7% of Northrop Grumman Corporation's tradable float, about 3.6 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does Northrop Grumman Corporation have too much debt?

It is moderate — Northrop Grumman Corporation's debt-to-equity is 0.95. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.

What is Northrop Grumman Corporation's capex?

Northrop Grumman Corporation spent $5.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.4 B. — as of 17 September 2026.

What is Northrop Grumman Corporation's cash flow?

Northrop Grumman Corporation generated $4.8 B of operating cash flow in FY25 and $3.3 B of free cash flow after $1.4 B of capital spending. Reported profit that year was $4.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.

Is Northrop Grumman Corporation's profit real cash?

Yes — over the last 3 fiscal years, 125% of Northrop Grumman Corporation's reported profit arrived as operating cash. In FY25, operating cash was $4.8 B against reported profit of $4.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.

How financially safe is Northrop Grumman Corporation?

On the balance sheet, the Z-score reads 3.33 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.

Where is Northrop Grumman Corporation in its business cycle?

Northrop Grumman Corporation's FY25 operating margin was 10.8%, against a 5-year band of 6.5%–15.8%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 10.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Northrop Grumman Corporation story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Northrop Grumman Corporation a stock worth studying right now?

This is not investment advice. The machine read: Northrop Grumman Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI